StockData
Amgen Inc logo

Amgen Inc (AMGN) stock

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới Q3 năm tài chính 2026, quý kết thúc ngày Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 17/3026% above fair value
$443.89−14.04 (-3.07%)

Close on Nov 18, 2026Market cap $239.98BP/E 25.7Yield 2.18%

Earnings

Amgen's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Feb 2, 2027
Q4 FY2026 · estimated, during market hours
Revenue, Q3 FY2026
$10.40B
+8.3% on a year earlier
Non-GAAP EPS, Q3 FY2026
$6.45
$5.64 a year earlier
Latest guidance
Issued
Nov 3, 2026 · 6 items

Quarterly results

Revenue and earnings per share from each of Amgen's earnings releases, newest first

QuarterReportedRevenueYoYEPSAdj. EPSSource
Q4 FY2026ended Dec 31, 2026Feb 2, 2027Expected–––––
Q3 FY2026ended Sep 30, 2026Nov 3, 2026after the close$10.40B+8.3%$7.08$6.45Release
Q2 FY2026ended Jun 30, 2026Aug 4, 2026during market hours$10.10B+9.8%$4.37$6.29Release
Q1 FY2026ended Mar 31, 2026Apr 30, 2026during market hours$8.60B+6.2%$3.34$5.15Release
Q4 FY2025ended Dec 31, 2025Feb 3, 2026during market hours$9.90B+8.8%$2.45$5.29Release
Q3 FY2025ended Sep 30, 2025Nov 4, 2025during market hours$9.60B+12.9%$5.93$5.64Release
Q2 FY2025ended Jun 30, 2025Aug 5, 2025during market hours$9.20B+9.5%$2.65$6.02Release
Q1 FY2025ended Mar 31, 2025May 1, 2025during market hours$8.10B+9.5%$3.20$4.90Release
Q4 FY2024ended Dec 31, 2024Feb 4, 2025during market hours$9.10B+11.0%$1.16$5.31Release
Q3 FY2024ended Sep 30, 2024Oct 30, 2024during market hours$8.50B+23.2%$5.22$5.58Release
Q2 FY2024ended Jun 30, 2024Aug 6, 2024during market hours$8.40B+20.0%$1.38$4.97Release
Q1 FY2024ended Mar 31, 2024May 2, 2024during market hours$7.40B+21.3%-$0.21$3.96Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Current guidance

Amgen's latest outlook for periods it has not reported yet, compared with what it said before

MetricPeriodGuidanceBeforeChangeGiven
Total revenuesFY2026$38.90B – $39.70B–NewNov 3, 2026
Total revenuesFY2026$38.20B – $39.40B$37.10B – $38.50BRaisedAug 4, 2026
EPSGAAPFY2026$18.34 – $19.28–NewNov 3, 2026
EPSGAAPFY2026$15.80 – $17.08$15.62 – $17.10NarrowedAug 4, 2026
EPSnon-GAAPFY2026$22.90 – $23.70–NewNov 3, 2026
EPSnon-GAAPFY2026$22.30 – $23.50$21.70 – $23.10RaisedAug 4, 2026
Capital expendituresFY2026$2.60B–NewNov 3, 2026
Capital expendituresFY2026$2.60B$2.60BReaffirmedAug 4, 2026
Share repurchasesFY2026$3.00B$3.00BReaffirmedAug 4, 2026
tax rateGAAPFY202614.5% – 16%–NewNov 3, 2026
tax ratenon-GAAPFY202615% – 16.5%–NewNov 3, 2026
tax rateGAAPFY202614.5% – 16%14.5% – 16%ReaffirmedAug 4, 2026
tax ratenon-GAAPFY202615% – 16.5%15% – 16.5%ReaffirmedAug 4, 2026

Guidance vs results

The last range Amgen gave before each report, against the figure it then reported. Full years add up the four quarters.

PeriodMetricGuidanceActualResult
FY2025EPS$20.60 – $21.40$21.85Σ4QAbove range
FY2025EPS (GAAP)$13.76 – $14.60$14.23Σ4QWithin range
FY2025Revenue$35.80B – $36.60B$36.80BΣ4QAbove range

Guidance history

Every forecast Amgen put in an earnings release, newest first

GivenMetricPeriodGuidanceChange
Nov 3, 2026Capital expendituresFY2026$2.60BNew
Nov 3, 2026EPSFY2026$22.90 – $23.70New
Nov 3, 2026EPSFY2026$18.34 – $19.28New
Nov 3, 2026tax rateFY202614.5% – 16%New
Nov 3, 2026tax rateFY202615% – 16.5%New
Nov 3, 2026Total revenuesFY2026$38.90B – $39.70BNew
Aug 4, 2026Capital expendituresFY2026$2.60BReaffirmed
Aug 4, 2026EPSFY2026$22.30 – $23.50Raised
Aug 4, 2026EPSFY2026$15.80 – $17.08Narrowed
Aug 4, 2026tax rateFY202614.5% – 16%Reaffirmed
Aug 4, 2026tax rateFY202615% – 16.5%Reaffirmed
Aug 4, 2026Share repurchasesFY2026$3.00BReaffirmed
Aug 4, 2026Total revenuesFY2026$38.20B – $39.40BRaised
Apr 30, 2026Capital expendituresFY2026$2.60BReaffirmed
Apr 30, 2026EPSFY2026$21.70 – $23.10Raised
Apr 30, 2026EPSFY2026$15.62 – $17.10Raised
Apr 30, 2026tax rateFY202614.5% – 16%Lowered
Apr 30, 2026tax rateFY202615% – 16.5%Lowered
Apr 30, 2026Share repurchasesFY2026$3.00BReaffirmed
Apr 30, 2026Total revenuesFY2026$37.10B – $38.50BRaised

Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.

Adjusted figures

Non-GAAP numbers Amgen reports itself, taken from its earnings releases

MeasureQ3 FY2026Q2 FY2026Q1 FY2026Q4 FY2025FY2025
non-GAAP operating income$4.70B$4.60B$3.70B$4.00B$16.20B
Non-GAAP net income$3.52B$3.42B$2.80B––
Non-GAAP EPS$6.45$6.29$5.15$5.29$21.84
free cash flow$3.70B$3.50B$1.50B$1.00B$8.10B

Read from the company's own earnings releases; hover a figure for the sentence it came from. Companies choose what to leave out of an adjusted number and there is no standard for it, so these are not comparable between companies the way the audited statements are. Margins here are computed from the adjusted revenue of the same period.

Press releases

Releases Amgen filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Results
  3. Results
  4. Results
  5. Results
  6. Results
  7. Results
  8. Results
  9. Results
  10. Results
  11. Results
  12. Results
  13. Results
  14. Update
  15. Update

See a number that looks wrong?